CRO QUALITY BENCHMARKING PHASE I SERVICE PROVIDERS (10TH EDITION)

Transcription

1 WORLDWIDE CLINICAL TRIALS COMPANY PERFORMANCE PROFILE, EXCERPT FROM CRO QUALITY BENCHMARKING - PHASE I SERVICE PROVIDERS, 10TH EDITION CRO QUALITY BENCHMARKING PHASE I SERVICE PROVIDERS (10TH EDITION) JUNE, 2018

2 INTRODUCTION IN THIS EXCERPT: The content for this excerpt was taken directly from CRO Quality Benchmarking - Phase I Service Providers report, June All or parts of the following sections are included in this excerpt: ISR Introduction, Methodology, Participant Criteria, Service Provider Performance and Loyalty Primary Section Takeaways, Company Service Quality Profiles, Worldwide Clinical Trials Performance Summary, Performance Across Service Providers, and About ISR. Cue the streamers. Don the party hats. Break out the champagne. That s right, folks. We ve been bringing you top notch CRO performance and selection data for an entire decade now. Welcome to the 10th edition of ISR s CRO Quality Benchmarking - Phase I Service Providers report. As ever, the goal of this report is to provide detailed information to aid in making informed decisions when outsourcing Phase I work. No doubt the CRO selection process is an onerous one; reviewing proposals, whittling providers down to a short list, and hearing bid defenses are time consuming and result in a lot of information to digest. And don t even get us started on contract negotiations. This report aims to simplify the process of provider selection by offering insights into the selection process and service provider performance. 305 qualified Phase I decision-makers participated in our survey to share their insights on topics such as selection drivers, perceptions of providers, and how well provider performance stacked up against their expectations. 46 Phase I providers received performance evaluations on 22 attributes across five categories (Budget Factors, Delivery Factors, Staff Characteristics, Accessibility, and Services). Based on customer feedback, ISR has introduced the Services scorecard this year. Respondents who have recent experience using a CRO for Central lab, Biostatistics, Data management, and/or Monitoring services rate how well providers performed on those specific services. These metrics will be particularly useful to sponsors looking to outsource work functionally or needing a provider with stand-out capabilities in one of these areas. This report is valuable for both sponsors and service providers. Sponsors use this information to understand the drivers that industry peers feel are important when selecting Phase I CROs. Search for CROs that may be a good fit for your needs after understanding how they performed for others along the dimensions most critical to your projects. Providers learn how sponsors select CROs in different decision-making scenarios so that you may tailor your proposals to appropriately trumpet the desired capabilities. Gain a better understanding of your strengths and weaknesses as seen through the eyes of your recent customers. See where other providers might hold competitive advantages and analyze service gaps that may need to be closed. For sponsors and service providers alike, the information contained in this report is useful for making educated decisions regarding Phase I outsourced work. Let ISR s ten years of experience in this arena do the legwork for you. 2

3 METHODOLOGY COLLECTION IN Q4, MINUTE WEB-BASED QUANTITATIVE SURVEY 305 RESPONDENTS FROM NORTH AMERICA, EUROPE, AND ASIA 3

4 Participant Criteria Respondents were required to pass several screening criteria to qualify and participate in this survey: Must work at a pharmaceutical company, biotech company, or medical device company Must have responsibility in at least one of several relevant areas. For example, Clinical Operations, Project Management, Executive Management, or Research and Development Management Must have involvement with outsourced Phase I trials within past 12 months Consolidation is nothing new to the contract services industry, and a number of companies featured in this report have been part of recent M&A activity. At ISR we know that integration of a new acquisition can take a significant amount of time; as such, companies acquired within the past months are still represented by the prior brand. 4

5 Number of Ratings Per Company Service Provider Accelovance 3 Altasciences (Vince, Algorithme) 6 BioPharma Services Inc. 8 Bioskin 5 Biotrial 10 Celerion 26 CHDR 8 Chiltern 11 Clinical Research Services (CRS) 5 Clinlogix 4 Covance 94 DataCeutics 3 DaVita Clinical Research 12 DCRI-Duke 12 Eurofins 22 Eurotrials 3 Frontage 10 ICON 59 Inamed 3 INC Research 35 inventiv Health Clinical 45 IQVIA/QuintilesIMS 85 Lambda 10 Respondent Ratings Service Provider Medpace 18 Medsource 4 NAMSA 5 Novotech 7 Nuvisan 10 Ora 5 PAREXEL 99 Pharm-Olam International 6 PPD 73 PRA 42 PRC Clinical 2 ProTrials 3 QPS 4 Quotient Clinical 19 Rho 5 SGS Life Sciences 12 Simbec 2 Spaulding Clinical 5 SynteractHCR 3 TKL Research 4 US Oncology 8 WCCT Global 13 Worldwide Clinical Trials 19 Total Ratings 847 Respondent Ratings Companies listed in bold print have been reviewed by 10 or more respondents. These providers have detailed company service quality profiles and are included in an in-depth performance analysis. 5

6 SERVICE PROVIDER PERFORMANCE AND LOYALTY CRO QUALITY BENCHMARKING PHASE I SERVICE PROVIDERS (10TH EDITION) 6

7 Primary Section Takeaways 1. Top Performers: Overall: Worldwide Clinical Trials, Biotrial, SGS Life Sciences Budget Factors: Worldwide Clinical Trials, Nuvisan, Lambda Delivery Factors: Biotrial, Worldwide Clinical Trials, SGS Life Sciences, Celerion Staff Characteristics: Worldwide Clinical Trials, Biotrial, DCRI-Duke, SGS Life Sciences Accessibility: Biotrial, SGS Life Sciences, Worldwide Clinical Trials Services: Worldwide Clinical Trials, inventiv Health Clinical, Celerion 2. Customer Loyalty: 2018 Top Performers: Worldwide Clinical Trials, Celerion, SGS Life Sciences, Biotrial 3-Year Rolling Average Top Performers: Worldwide Clinical Trials, SGS Life Sciences, Celerion, DaVita Clinical Research, Quotient Clinical 7

8 COMPANY SERVICE QUALITY PROFILES CRO QUALITY BENCHMARKING PHASE I SERVICE PROVIDERS (10TH EDITION) 8

9 Worldwide Clinical Trials (Base=19) Loyalty Component Scores Likelihood to recommend Likelihood to use again Overall satisfaction Industry Standard Research Performance Relative to Expectations Responsiveness Greatly exceeded my expectations Somewhat Somewhat exceeded exceeded my expectations my expectations Met my expectations Met my expectations Somewhat Somewhat fell short fell of my short expectations of my expectations Greatly fell Greatly short fell of my short expectations of my expectations Industry Standard Research 32% 42% 5% Clinic availability 26% 53% 5% Meeting overall project timelines Timely project communications Easy to work with 58% 5% Scientific knowledge of the Phase I unit's lead investigator Project manager quality Staff turnover 26% Access to patient populations 26% Operational excellence 68% Therapeutic expertise 74% Data quality 74% Local market/regulatory knowledge 74% Patient/volunteer recruitment 68% 5% Appropriateness of change orders 68% 5% Cost 5% 5% Access to "unique" tests, machines, equipment 79% Technology for real-time access to data Monitoring (n=12) 17% 8% 75% Data management (n=12) 25% 8% 67% Biostatistics (n=11) 27% 18% 55% Central lab (n=11) 18% 9% 73% 0% 20% 40% 60% 80% 100% % of Respondents 9

10 Performance Across Service Providers This cross-cro chart has been developed as a way for pharma companies and CROs to quickly gauge how CROs perform against their peers on a specific performance attribute. The metrics used in the following chart assign 3 points if respondents indicated the service provider greatly exceeded expectations, 1 point if they somewhat exceeded expectations, 0 points if they met expectations, -1 point if they somewhat missed expectations and -3 points if they greatly missed expectations. A service provider s scores are included on this chart if 10 or more respondents evaluate its performance on that attribute. Numbers are colored green if the score is >0.25 and red if the score is <

11 Access to unique tests, machines, equipment Access to patient populations Appropriateness of change orders CRO C Worldwide Clinical Trials (n=19) CRO A CRO B CRO D CRO E CRO F CRO G CRO H CRO I CRO J Clinic availability Cost Data quality Easy to work with Local market/ Regulatory knowledge Meeting overall project timelines Operational excellence Patient/volunteer recruitment Project manager quality Responsiveness Scientific knowledge of the Phase I unit s lead investigator Staff turnover Technology for realtime access to data Therapeutic expertise Timely project communications Central lab Biostatistics Data management Monitoring

12 Access to unique tests, machines, equipment Access to patient populations Appropriateness of change orders CRO K CRO L CRO M CRO N CRO O CRO P CRO Q CRO R CRO S CRO T CRO U Clinic availability Cost Data quality Easy to work with Local market/ Regulatory knowledge Meeting overall project timelines Operational excellence Patient/volunteer recruitment Project manager quality Responsiveness Scientific knowledge of the Phase I unit s lead investigator Staff turnover Technology for realtime access to data Therapeutic expertise Timely project communications Central lab Biostatistics Data management Monitoring

13 ABOUT US Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise. For more information about our off-the-shelf intelligence and custom research offerings, please visit our website at ISRreports.com, info@isrreports.com, or follow us on Send Us Your Feedback Because we are a service organization, we enjoy receiving feedback on our work. Please any comments, questions, or suggestions to info@isrreports.com. Copyright 2018 Industry Standard Research. All rights reserved. Act with confidence, ISR Reports and Industry Standard Research are trademarks of Industry Standard Research. All other trademarks are property of their respective holders. Information is subject to change since Industry Standard Research reserves the right to make changes without notice. While the information contained herein has been prepared from sources deemed to be reliable, Industry Standard Research reserves the right to revise the information without notice but has no obligation to do so. Use of this information is at your sole discretion. For more information, contact Industry Standard Research at Printed in the USA June, 2018.